Evaxion biotech expands its evx-03 dna vaccine program into non-small cell lung cancer

Copenhagen, denmark, june 23, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, today announced that it has selected evx-03 as the product candidate within its dna technology platform to target a new indication with planned regulatory filing in h2 2022.
EVAX Ratings Summary
EVAX Quant Ranking